Humanized mouse model: T cells in the pretherapy TME increase NK-cell viability and CD16 and CD25 expression after RTX therapy. Flow cytometric analysis of intratumoral NK cells before and after RTX therapy. Mice were inoculated on day 0 with Raji tumor cells mixed with PBMCs containing varying percentages of T cells. After tumors developed on day 20, FNAs were obtained, and mice were treated systemically with RTX (or TRA as control). On day 24 (4 days after mAb dose), a second FNAs were obtained and before to after therapy changes in NK-cell numbers (A), NK-cell CD16 expression (B), and NK-cell CD25 expression (C) were determined.